Pivotal bioVenture Partners

Summary

Pivotal bioVenture Partners appeared to be the VC, which was created in 2017. The main department of described VC is located in the San Francisco. The venture was found in North America in United States.

We can highlight the next thriving fund investment areas, such as Medical, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Fusion Pharmaceuticals, SutroVax, Bolt Biotherapeutics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The current fund was established by Tracy Saxton. We also calculated 3 valuable employees in our database.

The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this VC is 36 percentage points more often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The important activity for fund was in 2019. This Pivotal bioVenture Partners works on 15 percentage points more the average amount of lead investments comparing to the other organizations.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Pivotal bioVenture Partners, startups are often financed by Frazier Healthcare Partners, Wellcome Trust, Technology Development Fund. The meaningful sponsors for the fund in investment in the same round are Sofinnova Investments, Vivo Capital, Frazier Healthcare Partners. In the next rounds fund is usually obtained by Tekla Capital Management, TPG Growth, Roche Venture Fund.